IMPORTANCE Bacillus Calmette-Guérin (BCG) vaccination is commonly delayed in infants who are preterm and have low birth weights (LBW) despite the association of early vaccination with better vaccination coverage and potentially nonspecific benefits for survival.
B
acillus Calmette-Guérin (BCG) is the most widely administered vaccine worldwide. 1 It remains the only approved vaccine for the prevention of tuberculosis (TB), which globally affects more than 10 million individuals annually. 2 The BCG vaccine is usually given soon after birth to infants who were full term and reduces incidence of TB disease and TB-associated mortality in childhood. 3, 4 However, among the 15 million infants born preterm and 20 million born with low birth weight (LBW) each year worldwide, BCG is commonly delayed because of uncertainty about safety and immunogenicity. 5, 6 International and national guidelines are inconsistent on the timing of BCG vaccination in infants who are preterm and/or LBW, ranging between early vaccination and deferring BCG until discharge from hospital or at a follow-up appointment. The most recent World Health Organization (WHO) position paper highlights the lack of systematic evidence on safety and efficacy, particularly for infants with LBW.
7-11
Delayed administration of BCG has been reported to be associated with reduced vaccination coverage and equitability.
12-15 Two large, recent cohort studies from Ghana and Kenya showed that LBW was an independent risk factor for BCG vaccination delay, with 25% to 60% nonvaccination in the first 4 weeks of life and ongoing slow uptake thereafter. 12, 13 The observation that BCG vaccination is more delayed among home-born infants who have LBW suggests that parental concern about the infant's fragility may be a contributory factor. 12, 16 The current global vaccination action plan emphasizes increasing coverage and equitability by targeting groups underserved by current strategies.
17
Administering BCG vaccine shortly after birth, when the family is engaged with health care professionals, is logistically straightforward; however the safety, immunogenicity, and protective efficacy of BCG vaccine against TB is unclear in this population. Disseminated BCG disease is a potentially fatal complication among individuals who are immunocompromised, and the WHO advises against BCG vaccination of known HIVinfected infants. 18, 19 Suppurative BCG lymphadenitis is more common in neonates than older children, and risk is limited by dose reduction. 19 The concept that infants who are preterm and/or have LBW are immunologically immature prompts uncertainty about the risks of both morbidity and protective immunogenicity among these infants if they are vaccinated at birth. [20] [21] [22] [23] It has been suggested that delaying BCG vaccination in infants who are full term may result in an enhanced memory CD4 T-cell response; some studies on this topic have been inconsistent. [24] [25] [26] There is also increasing interest in potential heterologous effects of early BCG vaccination, reported to be associated with reduced all-cause mortality that cannot be explained by protection against TB alone.
27 The WHO has appealed for further evidence before modifying the Expanded Programme of Immunization recommendations. 11 We aimed to systematically review the published literature to address the following clinical question: in infants who are preterm and/or have LBW, is early BCG vaccination safe, immunogenic, and efficacious compared with delayed BCG vaccination?
Methods

Search Strategy and Selection Criteria
This meta-analysis is presented according to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. 28 Medline, Embase, and Global Health databases were searched using the Ovid interface without language or date restrictions. Search terms included multiple variants of terms BCG, prematurity, low-birth weight, and small for gestational age, additional to Medical Subject (MeSH) Headings (eMethods in the Supplement). Randomized clinical trials (RCTs) of BCG vaccination in newborns (without terms limiting the included population by gestational age or birth weight) were also searched. Snowball searching was performed by screening the references of retrieved studies. Experts in the field were contacted. The search was last updated on August 8, 2017. Predefined inclusion criteria were randomized clinical trials, cohort studies, or case-control studies that (1) included BCG vaccination of neonates who were preterm (those born at <37 weeks' gestational age), LBW (born weighing <2.5 kg), or both, and (2) reported safety, mortality, immunogenicity, measures of vaccine take (such as tuberculin skin test [TST] conversion), or efficacy against TB disease. Studies were included if they compared BCG vaccination in infants who were preterm and/or LBW and less than or equal to 7 days old vs those more than 7 days old, infants who were preterm vs full term, or infants with LBW vs those with normal birth weights (NBW). Including the second and third analyses allowed comparison with infants who were full term and/or had NBWs as a reference population for safety, immunogenicity, and efficacy.
We examined safety data on local and regional reactogenicity (eg, erythema, induration, ulceration, scarring, abscess formation, cutaneous lesions, and lymphadenitis); systemic adverse reactions (eg, osteomyelitis and disseminated BCG disease); mortality; measures of immunogenicity, including T-cell responses to purified protein derivative (PPD), BCG, or specific Mycobacterium tuberculosis antigens or antigen pools; reported vaccine take assessments including TST conversion; and protective efficacy against TB disease.
Screening and Data Extraction
We excluded studies of infants who were full term and/or NBW only, studies without specific outcome data on infants who were preterm or LBW, studies with duplicate data, and studies reporting only responses to heterologous nonMycobacterial antigens. After removal of ineligible studies and duplicates, 2 authors (S.B. and A.M.) independently screened all titles and abstracts. If either reviewer thought an abstract may meet inclusion criteria, the full text of the article was reviewed. Discrepancies were resolved by the senior author (J.A.B.). Data were extracted into tables that included study location; design; methods of recruitment; sample size; population characteristics; age at vaccination; BCG strain; methods used for measuring outcomes; and results on safety, immunogenicity, TST conversion, and protective efficacy against TB. Where indicated, study authors were contacted to request additional data or clarification as needed.
Risk of Bias Assessment
Two independent reviewers (S.B. and H.D.) assessed the included studies using tools from the Cochrane collaboration.
29,30
For domains with insufficient information for adequate assessment risk of bias (such as undescribed randomization procedures), and where this domain was likely to affect the outcome of interest, a judgement of high risk was made. For studies presenting safety alone, methodological quality assessment was restricted to this outcome.
Statistical Analysis
For studies comparing infants who were preterm and/or had LBW and were vaccinated at birth with those who experienced vaccination at later points, we performed metaanalyses using random-effects models. We used the MantelHaenszel method for dichotomous data and presented the results as relative risks (RR) with 95% CIs. Statistical heterogeneity was assessed using the I 2 test for each outcome. Sensitivity analyses were planned and performed for assessing the effects of heterogeneous studies and studies with high risk of bias by sequential exclusion. Meta-analysis was performed using Review Manager (RevMan) version 5.3 (Cochrane Collaboration).
Results
The search returned 1552 articles. After removal of duplicate data and screening, 40 articles were identified ( Figure 1 ).
14,20-23,31-65
Most studies were prospective cohorts or randomized clinical trials, conducted predominantly between 1990 and 2017 in Africa (k = 14 [where k indicates the number of studies]), Asia (k = 10), Europe (k = 8), South America (k = 5) and the Middle East (k = 3). One study included 2019 infants who were preterm and 2419 newborns who had LBW who had received early BCG vaccination but did not report safety outcomes independently from infants who were full term and/or had NBWs. In this case, individual patient data were obtained for post hoc analysis.
48
Overall, BCG vaccination was administered to 10 568 clinically stable neonates who were preterm and/or had LBW and aged 7 days or younger. Delayed vaccination was administered to 4310 infants at 8 days to 12 months after birth. The most commonly reported vaccination points were when the infant was near full term gestational age, had reached a weight of more than 2 kg or 2.5 kg, or was discharged from the hospital. Almost all infants were vaccinated by 6 months after birth. Gestational ages for infants who were preterm ranged from 26 to 37 weeks, and birth weights for infants identified as having LBW rangedfrom0.69kgto2.5kg.
Risk of Bias Assessment
Most studies were of moderate or high risk of bias. The most common causes of potential bias were lack of assessor blinding, inadequate assessment or adjustment for other prognostic factors, and loss to follow-up. For RCTs, randomization and concealment procedures were often inadequately described. Summaries are provided in eFigures 1-4 in the Supplement. Only data on infants who were preterm and/or LBW and had follow-up adequate to record scar formation (n = 515) or TST conversion (n = 397) were included.
Safety, Reactogenicity, and Mortality
Six studies evaluated safety. A large RCT from Guinea-Bissau reported enlarged lymph nodes at 6 months in 12 of 1416 infants (0.8%) with LBW who were vaccinated early and 7 of 1411 infants (0.5%) with LBW who were vaccinated at later points (reported P = .28). 62 A trial in India on 180 neonates born between 31 to 33 weeks' gestational age reported 2 infants in each of the early and late vaccination groups with nonsuppurative lymphadenopathy (a total of 4 individuals). 21 There were no other adverse reactions, and meta-analysis was not possible. The formation of BCG scars (defined by study authors) was reported in 7 studies, with no significant difference between early and delayed vaccination in meta-analysis ( Figure 2A) and later vaccination. One study comparing infants who were moderately preterm and vaccinated within 7 days of birth or at 34 weeks' postconception age reported no difference at age 6 months in interferon-γ levels in the unstimulated serum of infants who had not responded to the TST.
21
TST Conversion
All 7 studies of TST conversion (with thresholds defined by study authors) reported no significant difference between early and delayed BCG vaccination. 14,20-23,31,32 The pooled estimate in meta-analysis also showed no difference and low heterogeneity between studies ( Figure 2B ). We performed post hoc sensitivity analyses for both BCG scar formation and TST conversion by assessing changes in pooled effect size after exclusion of 1 study of neonates who were full term and IUGR, 20 the only retrospective study, 14 and 1 study where delayed vaccination was performed relatively early, at 34 weeks postconception. 21 We found no significant changes in the pooled estimate or estimated heterogeneity after these exclusions. Funnel plots of included studies showed no indication of nonsymmetry, suggesting minimal reporting bias (eFigure 5 in the Supplement).
Efficacy
No studies reported efficacy of BCG against TB disease. In an RCT 61 of 2424 infants, there were no deaths in infants who had LBW and were exposed to TB in either the early or delayed BCG arms. and 2019 who were preterm who had all received early BCG vaccination; this study included detailed reporting of adverse reactions. Individual patient data were obtained and post hoc comparisons made with 8299 infants who were full term and/or had NBWs and received early BCG vaccination. Across all trial participants, 22 grade 3 and 4 vaccine-associated adverse reactions occurred, including keloid scars (n = 16), suppurative lymphadenitis (n = 5), and disseminated BCG disease (n = 1). The relative risk of suppurative lymphadenitis in infants who had LBW (0.12%) compared with infants who had NBWs (0.02%) was sizeable, but low frequency and a lack of significance (relative risk, 5.7 [95% CI, 0.95-34]), as well as a lack of adjustment for the likely confounding factor of HIV status, which was not systematically assessed at birth, compromised the findings. There were no differences in other safety 45 reported an increased risk of adenitis in infants who were preterm, although quantitative data were not presented. Several studies compared BCG scar formation between infants who were preterm and/or had LBW and those who were full term and/or had NBWs, with an indication of less reactogenicity particularly in the preterm group ( Figure 3) . Reported measures of immunogenicity (lymphocyte proliferation and migration tests, cytokine responses, including tumor necrosis factor, interferon-γ, and interleukin 2) were more frequently studied in infants who had LBW, with no clear differences compared with those who had NBWs. Most studies comparing TST conversion between infants who were preterm and full term reported reduced responses in the preterm group, although the data were not suitable for metaanalysis ( Figure 3) .
The use of different outcomes and summary statistics in each study, considerable heterogeneity in study design, and risks of bias in these predominantly observational studies meant that they were not suitable for pooled or metaanalysis. The differences in findings between studies did not suggest a pattern based on BCG vaccine strain.
Three studies included infants who were preterm and/or had LBW and were vaccinated early and reported TB disease outcomes. 45 Heterogeneity: τ 2 = 0.00; χ 2 6 = 0.62, (P >.09); I 2 = 0% Test for overall effect: z = 0.36 (P = .72)
Risk of tuberculin skin test conversion B
A, Meta-analysis of the risk of developing a bacillus Calmette-Guérin (BCG) scar. B, Meta-analysis of tuberculin skin test conversion in infants who are preterm and/or had low birth weights for BCG vaccination within 7 days or at a later point. 9 days found that LBW was not an independent risk factor for all-cause 12-month mortality. However, only about half of all deaths and just over half of survivors had birth weight data.
Safety and
Immunogenicity of Early BCG Vaccination in Infants Who Are Preterm and/or Have Low Birth Weights Original Investigation
46
Discussion
We report the first systematic review of BCG safety, immunogenicity, and protective efficacy in infants who are preterm and/or LBW. There was no evidence of increased BCGassociated adverse events when vaccination was administered within 7 days of birth in clinically stable neonates, compared with vaccination at later points. Meta-analyses of BCG scar formation and TST conversion suggested no differences between the 2 groups. Immunogenicity could not be evaluated owing to inadequate data. No studies reported efficacy against TB disease in BCG within 7 days vs vaccination at later points. Studies of adverse reactions comparing infants who were preterm and/or had LBW to infants who were full term and/or had NBWs predominantly reported no differences.
Strengths
There were a large number of infants who were preterm and/or had LBW (n = 7281) vaccinated early or late, informing conclusions on safety. In most studies, reactogenicity was measured using BCG scar formation or TST, allowing crosscomparison and greater confidence in observed effects. Across studies, neonates with signs of severe illness were excluded. Where defined, common criteria for exclusion were neonatal sepsis, fever, assisted ventilation, hemodynamic instability, congenital malformations, asphyxia, maternal serious illness, TB, known HIV, or hepatitis B. Only 7 studies clearly included neonates younger than 30 weeks' gestational age or less than 1.5 kg birth weight. This is unsurprising, as most extremely neonates who are preterm and/or had very LBW may be clinically unstable in the first few days of life. Furthermore, neonates born at more than 30 weeks' gestational age and weighing more than 1.5 kg constitute the largest portion of the overall cohort of infants who are preterm and/or had LBW, justifying a focus on this cohort globally.
Safety
Four studies, 3 of which had large losses to follow-up, reported all-cause mortality. None showed increased mortality among infants who had LBW and received early BCG vaccination, compared with either (1) vaccination at later points in infants who had LBW or (2) BCG vaccination within 7 days in infantswhohadNBW.
46,61-63 Subgroup analysis of raw data from the RCT by Hawkridge et al 48 showed a nonsignificant increase in lymphadenitis in infants who had LBW but was unadjusted for the major confounder of maternal HIV, which is associated with preterm birth, LBW, and TB risk. 67 The overall incidence of lymphadenitis was low (0.12% in infants who had LBW) and is unlikely to be of clinical importance in the context of current WHO advice. There was no increase in lymphadenitis in infants who were preterm, but most studies reported lower markers of reactogenicity in the form of BCG scar formation compared with infants who were full term ( Figure 3) . No cases of disseminated BCG were reported in infants who are preterm and/or LBW. In comparison, Hesseling et al 18 reported a 1% incidence of disseminated BCG disease in HIVinfected infants. There is currently uncertainty regarding the 
Immunogenicity and TST Conversion
Few studies evaluated immunogenicity by antigen-specific T-cell cytokine responses to PPD, BCG or Mycobacterium tuberculosis antigens. Tuberculin skin test was the most frequently reported marker of vaccine response. The traditional view is that TST conversion reflects the development of delayed-type hypersensitivity (DTH) to mycobacterial antigens and thus vaccine take. 
Limitations
In all studies, gestational age was estimated using Ballard or Dubowitz scores and may be inaccurate. Most RCTs had poorly described randomization, allocation concealment methods, and blinding. Many studies were unblinded. This may be of relevance because TST is known to be operator dependent, but it is difficult to gauge the direction of this potential bias. The TSTs were performed at varying times after BCG vaccination using varying methods. Assessment of confounders of TST reaction, such as malnutrition, HIV, and concurrent TB infection, were scarcely reported.
72 While there appears to be a high degree of consistency in the outcomes for the studies included in the meta-analysis, these factors may have contributed to the significant variation in TST and BCG scar outcomes across all studies. Few studies actively monitored for adverse reactions. Notably, Hawkridge et al 48 conducted 3 months of active follow-up of 4851 infants for adverse reactions. However, many studies suffered from large losses to follow-up, and the risk of underestimation of adverse reactions is significant. Different BCG strains were used between studies, possibly giving variable reactogenicity.
74
Cohort studies comparing BCG responses in infants who were preterm vs those who were full term suggested a direction of effect of weaker BCG scar formation, TST conversion, and lymphocyte proliferation in infants who were preterm, which could not be confirmed with meta-analysis. We would caution against drawing conclusions based on these data. Importantly, there is no evidence that infants who are preterm would respond better if vaccination occurs more than 7 days after birth, because 3 of the 5 studies comparing delayed BCG vaccination in infants who are preterm vs full term showed less BCG scar formation, TST conversion, and lower lymphocyte proliferation test responses in infants who were preterm.
22,32,41,42,51
Conclusions and Policy Implications
Most studies included healthy neonates born at more than 30 weeks' gestational age or weighing more than 1.5 kg and reported no increased risk of adverse reactions or infant mortality after BCG vaccination within 7 days of birth compared with BCG vaccination at later points. Vaccination within 7 days resulted in similar rates of BCG scar formation and TST conversion compared with later vaccination. No studies evaluated protective efficacy comparing early vs late BCG. Assessment of TB disease outcomes would require large RCTs in areas with high TB burden. Future research should focus on addressing the highlighted methodological weaknesses, measuring specific immune responses, including antigen-specific intracellular cytokine responses to purified protein derivative or Mycobacterium tuberculosis antigens. 25 Our independent findings strongly support the most recent WHO advice of early vaccination in healthy infants born moderately preterm and with moderate LBW, and synthesizes more extensively the evidence for early vaccination safety in this population. 11 The question of when best to vaccinate these neonates at the local level requires consideration of this evidence, the potential outcomes of reduced vaccine coverage if BCG vaccination is delayed, service delivery factors, and the results of further trials on nonspecific outcomes of early BCG vaccination. At present, on the basis of current evidence, a uniform policy of early BCG vaccination of clinically stable infants who are preterm and/or had LBW appears justified. Role of the Funder/Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. 
